Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of E626. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NT5E | P21589 | 1/20 | 0.76 |
| ▸ | TGM2 | P21980 | 1/20 | 0.71 |
| ▸ | IMPDH2 | P12268 | 7/20 | 0.70 |
| ▸ | IMPDH1 | P20839 | 2/20 | 0.70 |
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.67 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.67 |
| ▸ | KRAS | P01116 | 6/20 | 0.64 |
| ▸ | HINT1 | P49773 | 1/20 | 0.63 |
| ▸ | FUT5 | Q11128 | 1/20 | 0.63 |
| ▸ | CA5A | P35218 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| E626 SCHEMBL2775605 | 0.99 | NT5E (0.77) | NT5ETGM2IMPDH2IMPDH1TAS1R3 | |
| E626 SCHEMBL9386996 | 0.96 | NT5E (0.81) | NT5ETGM2IMPDH2IMPDH1TAS1R3 | |
| E626 SCHEMBL21803790 | 0.95 | NT5E (0.83) | NT5ETGM2IMPDH2IMPDH1TAS1R3 | |
| E626 SCHEMBL20277596 | 0.95 | NT5E (0.83) | NT5ETGM2IMPDH2IMPDH1TAS1R3 | |
| E626 SCHEMBL18763818 | 0.95 | NT5E (0.83) | NT5ETGM2IMPDH2IMPDH1TAS1R3 | |
| E626 SCHEMBL18785103 | 0.95 | NT5E (0.83) | NT5ETGM2IMPDH2IMPDH1TAS1R3 | |
| E626 SCHEMBL5854 | 0.95 | NT5E (0.83) | NT5ETGM2IMPDH2IMPDH1TAS1R3 | |
| E626 SCHEMBL20677331 | 0.95 | NT5E (0.83) | NT5ETGM2IMPDH2IMPDH1TAS1R3 | |
| E626 SCHEMBL21163348 | 0.95 | NT5E (0.83) | NT5ETGM2IMPDH2IMPDH1TAS1R3 | |
| E626 SCHEMBL165027 | 0.95 | NT5E (0.83) | NT5ETGM2IMPDH2IMPDH1TAS1R3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105050414-A | Methods and compositions for affecting flavor and odor characteristics of consumer products | MARAXI INC | 2015-11-11 | — | — | CN | claimed |
| CN-1896264-A | Preparation method of nucleoside triphosphate | UNIV NANJING POLYTECHNIC (CN) | 2007-01-17 | — | — | CN | claimed |
| US-20240218009-A1 | NOVEL FORMS OF CYCLIC DINUCLEOTIDE COMPOUNDS | MERCK SHARP & DOHME LLC (US) | 2024-07-04 | — | — | US | disclosed |
| WO-2024119224-A1 | ELECTROCHEMICAL CELL AND USES THEREOF | AUSTRALIAN NATIONAL UNIVERSITY (AU) | 2024-06-13 | — | — | WO | disclosed |
| US-20240182511-A1 | NOVEL FORMS OF CYCLIC DINUCLEOTIDE COMPOUNDS | MERCK SHARP & DOHME LLC (US) | 2024-06-06 | — | — | US | disclosed |
| CN-117897476-A | Microbial cell factory for producing vitamin B compounds | 拜奥信尼亚私营有限责任公司 | 2024-04-16 | — | — | CN | disclosed |
| WO-2023048291-A1 | tRNA, AMINOACYL-tRNA, POLYPEPTIDE SYNTHESIS REAGENT, UNNATURAL AMINO ACID INCORPORATION METHOD, POLYPEPTIDE PRODUCTION METHOD, NUCLEIC ACID DISPLAY LIBRARY PRODUCTION METHOD, NUCLEIC ACID/POLYPEPTIDE CONJUGATE, AND SCREENING METHOD | 富士フイルム株式会社 | 2023-03-30 | — | — | WO | disclosed |
| WO-2022225827-A1 | NOVEL FORMS OF CYCLIC DINUCLEOTIDE COMPOUNDS | MERCK SHARP & DOHME LLC (US) | 2022-10-27 | — | — | WO | disclosed |
| WO-2022216577-A1 | NOVEL FORMS OF CYCLIC DINUCLEOTIDE COMPOUNDS | MERCK SHARP & DOHME LLC (US) | 2022-10-13 | — | — | WO | disclosed |
| WO-2022198259-A1 | TREATMENT METHODS FOR PULMONARY ARTERIAL HYPERTENSION | THE HEART RESEARCH INSTITUTE LTD (AU) | 2022-09-29 | — | — | WO | disclosed |
| CN-114903900-A | PDE9 inhibitors for the treatment of peripheral diseases | 伊马拉公司 | 2022-08-16 | — | — | CN | disclosed |
| US-20050053966-A1 | Apparatus and method for the analysis of nucleic acids hydbridization on high density NA chips | POPONIN VLADIMIR (US) | 2005-03-10 | — | — | US | disclosed |
| EP-1490678-A2 | COMPOSITIONS AND METHODS FOR MODELING BACILLUS SUBTILIS METABOLISM | Genomatica, Inc. (US) | 2004-12-29 | — | — | EP | disclosed |
| US-6826488-B1 | CRYSTAL OF BACTERIAL INOSINE MONOPHOSPHATE DEHYDROGENASE PRODUCED FROM PURIFIED AND ACTIVE ENZYME OBTAINED FROM PURE CULTURE OF STREPTOCOCCUS PYOGENES | THE UNIVERSITY OF CHICAGO | 2004-11-30 | — | — | US | disclosed |
| WO-2003081207-A2 | COMPOSITIONS AND METHODS FOR MODELING BACILLUS SUBTILIS METABOLISM | GENOMATICA, INC. (US) | 2003-10-02 | — | — | WO | disclosed |
| US-20020123050-A1 | Apparatus and method for analysis of nucleic acids hybridization on high density NA chips. | VIRTUAL PRO, INC. | 2002-09-05 | — | — | US | disclosed |
| US-6376177-B1 | Apparatus and method for the analysis of nucleic acids hybridization on high density NA chips | VIRTUAL PRO, INC. | 2002-04-23 | — | — | US | disclosed |
| US-5780253-A | RAPID IDENTIFICATION OF ENZYME INHIBITORS TO PREVENT CONVERSION OF IONOSINE MONOPHOSPHATE TO ADENOSINE MONOPHOSPHATE AND GUANOSINE MONOPHOSPHATE | SANDOZ LTD. (CH) | 1998-07-14 | — | — | US | disclosed |
| US-5780254-A | Method for detection of herbicides | SANDOZ LTD (CH) | 1998-07-14 | — | — | US | disclosed |
| US-4701323-A | PURINES CONJUGATED TO ANTIGENS | IOWA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 1987-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240218009-A1 | NOVEL FORMS OF CYCLIC DINUCLEOTIDE COMPOUNDS | STING1, IFNAR1, CGAS | NT5E 374/4885TGM2 3569/4885IMPDH2 242/4885 |
| US-20240182511-A1 | NOVEL FORMS OF CYCLIC DINUCLEOTIDE COMPOUNDS | STING1, IFNAR1, CGAS | NT5E 331/4885TGM2 4020/4885IMPDH2 231/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.